Article

Objectives: To characterize further the clinical manifestations and the efficacy of growth hormone (GH) replacement therapy in patients with adult-onset growth hormone deficiency (GHD) reported in the KIMS (Pfizer's international metabolic database) as caused by traumatic brain injury (TBI) and to compare them with nonirradiated patients whose GHD was due to a nonfunctioning pituitary adenoma (NFPA). Design: Observational study. Setting: Subjects selected from the KIMS database. Participants: Fifty-one patients with GHD resulting from TBI and 688 patients with GHD resulting from NFPA. Both groups were selected from the KIMS and had adult-onset GHD with GH replacement therapy only after KIMS entry and before and after KIMS entry. Interventions: Not applicable. Main Outcome Measures: Age, body mass index, age at disease onset, age at disease diagnosis, age at KIMS entry, final height, GH peak at testing, GH replacement dose, routine biochemical analysis, clinical manifestations of disease, and quality of life measurements. Results: Patients with TBI were significantly younger at study entry and were younger both at pituitary disease onset and at GHD diagnosis, but they showed a significant delay in treatment. When comparing patients not treated with GH before entering in the KIMS, patients with TBI were significantly shorter (167.2 +/- 1.7cm) than those with NFPA (171.6 +/- 0.4cm) in final height. TBI patients had lower GH reserves than NFPA patients, and although the latter group experienced more positive changes, both groups benefited from GH replacement therapy. Conclusions: Patients with GHD due to TBI showed a significant reduction in height and a reduction in pituitary GH reserve and were diagnosed and treated with inappropriate delay. (C) 2005 by American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.

MAIN - MAS

Langue : ANGLAIS